| Mortality reduction by antiadrenergic modulation of arrhythmogenic substrate: significance of combining beta blockers and amiodarone. | |
| | |
MedLine Citation:
|
PMID: 10568664 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Over the last 3 decades, there have been numerous experimental and clinical studies that utilized beta blockers for acute as well as chronic myocardial syndromes, especially in the setting of myocardial infarction in which the focus has been on mortality reduction. The results of these studies demonstrated the benefits of these agents at all stages of coronary artery disease. Although these data have always indicated that beta blockade per se is an antiarrhythmic as well as an antifibrillatory mechanism, the recognition of this phenomenon has been slow in finding universal appreciation. More recent studies have evaluated the additive role of beta blockers to newer therapies. A number of investigations have now established that this class of drugs does exert antifibrillatory action in preventing the occurrence of ventricular tachycardia (VT) and ventricular fibrillation (VF), thereby reducing sudden arrhythmic death and prolonging survival. It is of interest that 2 of the leading antiarrhythmic drugs, amiodarone and sotalol, also have antiadrenergic properties. This article reviews the expanding role of beta-blocking drugs in the control and prevention of life-threatening ventricular tachyarrhythmias with a particular focus on the evidence for synergistic benefits when they are combined with other interventions, especially amiodarone. |
| | |
Authors:
|
K O Ogunyankin; B N Singh |
Related Documents
:
|
6826944 - Pharmacologic treatment of cardiac arrhythmias: 25 years of progress. 3607364 - Differing electrophysiological effects of class ia, ib and ic antiarrhythmic drugs on g... 19221604 - Cardiac alterations in human african trypanosomiasis (t.b. gambiense) with respect to t... 20873974 - Supraventricular tachycardia in neonates: antiarrhythmic drug choice dilemma. 21924224 - Nanoemulsions as self-emulsified drug delivery carriers for enhanced permeability of po... 10672634 - Acamprosate, but not naltrexone, inhibits conditioned abstinence behaviour associated w... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: The American journal of cardiology Volume: 84 ISSN: 0002-9149 ISO Abbreviation: Am. J. Cardiol. Publication Date: 1999 Nov |
Date Detail:
|
Created Date: 1999-12-01 Completed Date: 1999-12-01 Revised Date: 2005-11-16 |
Medline Journal Info:
|
Nlm Unique ID: 0207277 Medline TA: Am J Cardiol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 76R-82R Citation Subset: AIM; IM |
Affiliation:
|
Division of Cardiology, Bassett Healthcare, Cooperstown, New York 13326, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
administration & dosage*,
adverse effects Amiodarone / administration & dosage*, adverse effects Anti-Arrhythmia Agents / administration & dosage*, adverse effects Drug Therapy, Combination Electrocardiography / drug effects* Humans Survival Rate Tachycardia, Ventricular / drug therapy*, etiology, mortality Treatment Outcome Ventricular Fibrillation / drug therapy*, etiology, mortality |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Anti-Arrhythmia Agents; 1951-25-3/Amiodarone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Concomitant device and drug therapy: current trends, potential benefits, and adverse interactions.
Next Document: Lessons from antiarrhythmic trials involving class III antiarrhythmic drugs.